Table 1.
Clinical trials related to the baricitinib for COVID-19 treatment
| Study title | Status* | Number enrolled | Phase | Ages eligible for study | Reference |
|---|---|---|---|---|---|
| Baricitinib therapy in COVID-19 | Completed | 12 | Phase 2/3 | 18–85 years (adult, older adult) | [79], NCT04358614 |
| A study of baricitinib (ly3009104) in participants with COVID-19 | Completed | 1585 | Phase 3 | 18 years and older (adult, older adult) | [15], NCT04421027 |
| Treatment of moderate to severe coronavirus disease (COVID-19) in hospitalized patients | Recruiting | 800 | Phase 2 | 18 years and older (adult, older adult) | NCT04321993 |
| Baricitinib in Hospitalized Covid-19 Patients with Diabetes Mellitus | Recruiting | 382 | Phase 3 | 18 years and older (adult, older adult) | NCT04970719 |
| Baricitinib Compared to Standard Therapy in Patients With COVID-19 (BARICIVID-19) | Not yet recruiting | 126 | Phase 2 | 18 years and older (adult, older adult) | NCT04393051 |
| Baricitinib for corona virus pneumonia (COVID-19): a therapeutic trial (BREATH) | Not yet recruiting | 13 | Phase 2 | 18–74 years (adult, older adult) | NCT04399798 |
| A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER-PEDS) (COV-BARRIER) | Not yet recruiting | 24 | Phase 3 | 2–18 years (child, adult) | NCT05074420 |
| Efficacy and Safety of Baricitinib in Patients with Moderate and Severe COVID-19 | Not yet recruiting | 480 | Phase 3 | 18–80 years (adult, older adult) | NCT05056558 |
| Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults (COVID-AGE) | Completed | 576 | – | 70 years and older (older adult) | NCT04362943 |
*Please refer to https://clinicaltrials.gov/ for more details